Sarepta price target lowered to $75 from $80 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...
Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...
bovnews8h
Why Did H.C. Wainwright Give Energy Fuels Inc (UUUU) Stock Buy Rating?
On Friday, Energy Fuels Inc (UUUU) stock saw a modest uptick, ending the day at $7.29 which represents a slight increase of $0.49 or 7.21% from the prior close of $6.8. The stock opened at $7.1 and ...
bovnews6h
Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright
H.C. Wainwright has recently raised Syros Pharmaceuticals Inc (SYRS) stock to Buy rating, as announced on November 4, 2020, according to Finviz. Earlier, on September 22, 2020, Alliance Global ...
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Thanks to the Securities and Exchange Commission, you don't have to. Artificial intelligence (AI) has been the stock market's ...
manilatimes15h
Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 ...
Stocktwits on MSN2h
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges
Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...